acf/google-ad-placement

Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

Biotech

News

General

A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours85% and 77% of patients treated with a single dose of

Axsome Therapeutics Announces FDA Approval Of SYMBRAVO For The Acute Treatment Of Migraine With Or Without Aura In Adults; 85% And 77% Of Patients Treated With A Single Dose Of SYMBRAVO Did Not Require Migraine Rescue Medication Within 24 Hours In Two Phase 3 Studies - Axsome Therapeutics (NASDAQ:AXSM)

Benzinga Newsdesk

Axsome Therapeutics

AXSM

Axsome Therapeutics Announces FDA Approval Of SYMBRAVO For The Acute Treatment Of Migraine With Or Without Aura In Adults; 85% And 77% Of Patients Treated With A Single Dose Of SYMBRAVO Did Not Require Migraine Rescue Medication Within 24 Hours In Two Phase 3 Studies

Comments